Home > Insider Trading > Filing (0001415889-25-005841)

Filing Details

Accession Number:: 0001415889-25-005841
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-02-27 16:05:29
Reporting Period:: 2025-02-21

Filing Date:: 2025-02-27
Accepted Time:: 2025-02-27 16:05:29
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1831828	Vera Therapeutics Inc.	VERA	Pharmaceutical Preparations (2834)	812744449

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1859453	Marshall Fordyce	C/O Vera Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 1200 Brisbane CA 94005	President And Ceo	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Class A Common Stock	Disposition	2025-02-21	10,613	$27.89	213,740	No	4	S	Direct
Class A Common Stock	Disposition	2025-02-26	7,975	$27.55	205,765	No	4	S	Direct
Class A Common Stock	Disposition	2025-02-26	1,100	$28.32	204,665	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Class A Common Stock	222,030	Indirect	By GRAT

Footnotes

The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of three (3) business days, beginning on February 21, 2025 and ending on February 25, 2025.
Pursuant to Rule 16a-3(g)(2) and (3).
Shares sold to cover tax withholding obligations associated with the vesting of RSUs pursuant to an election intended to satisfy the conditions of Rule 10b5-1(c) made by the Reporting Person on August 26, 2022.
The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.37 to $29.80, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024.
The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.24 to $28.21, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.25 to $28.42, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.